

AD _____

Award Number: DAMD17-02-1-0492

TITLE: Suppression of NFkB by Tetrathiomolybdate Inhibits Tumor Angiogenesis and Enhances Apoptosis in Human Breast Cancers

PRINCIPAL INVESTIGATOR: Quintin Pan, Ph.D.

CONTRACTING ORGANIZATION: The University of Michigan
Ann Arbor, MI 48109-1274

REPORT DATE: May 2003

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040206 115

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2003	3. REPORT TYPE AND DATES COVERED Annual Summary (1 May 2002 - 30 Apr 2003)	
4. TITLE AND SUBTITLE Suppression of NFkB by Tetrathiomolybdate Inhibits Tumor Angiogenesis and Enhances Apoptosis in Human Breast Cancers			5. FUNDING NUMBERS DAMD17-02-1-0492	
6. AUTHOR(S) Quintin Pan, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Michigan Ann Arbor, MI 48109-1274 E-Mail: qpan@med.umich.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) <p>Angiogenesis, the formation of capillaries from pre-existing blood vessels, is essential for sustained growth of solid tumors. Numerous studies have shown that copper is required to modulate several pro-angiogenic factors. However, the specific effects of copper homeostasis on tumor angiogenesis have not been extensively studied. Our preliminary studies demonstrated that tetrathiomolybdate, a potent and novel copper chelator, blocks tumor growth and angiogenesis. We hypothesize that TM is inhibiting tumor angiogenesis by decreasing levels of VEGF, bFGF, IL-6, and IL-8 through interference with the NFkB signaling cascade. In this proposal, the molecular mechanism whereby TM regulates NFkB expression and activity will be investigated. We will establish if the NFkB transcription factor complexes, p50, p52, RelA, and RelB, are regulated by TM using Western blot analysis and gel shift assays. Furthermore, using a reporter gene system, we will ascertain if TM regulation of VEGF, bFGF, IL-6, and IL-8 is a direct consequence of NFkB signal inhibition. The studies as outlined will help us better understand the role of copper deficiency in tumor angiogenesis and may lead to a more specific and potent global anti-angiogenic approach to treat breast cancer.</p>				
14. SUBJECT TERMS NFkB, Tetrathiomolybdate, Breast Cancer				15. NUMBER OF PAGES 7
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	3
Body.....	3-6
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6
References.....	6

Introduction:


The NF κ B/Rel family of transcription factors is comprised of RelA, RelB, c-Rel, p50 (nf κ b1), and p52 (nf κ b2) (1). In recent years, evidence linking uncontrolled NF κ B activity to oncogenesis has emerged. NF κ B has been shown to regulate genes important for invasion, angiogenesis, and metastasis. These include pro-angiogenic factors, such as VEGF, IL-6, and IL-8, matrix metalloproteinases, urokinase plasminogen activator (uPA), and cell adhesion molecules, such as ICAM-1 and VCAM-1 (2-6). Blocking NF κ B activity in human ovarian cancer cells was shown to inhibit VEGF and IL-8 expression resulting in a decrease in tumor angiogenesis (7). Using SUM149 human inflammatory breast cancer cells, we demonstrate that p50 (nf κ b1) and RelA protein levels are decreased in response to TM. Our preliminary data indicate that TM also was able to block NF κ B-dependent transcription in these cells. Moreover, apoptosis was increased 2-fold in SUM149 cells following TM treatment. Taken together, our data lead us to hypothesize that TM is blocking tumor angiogenesis by decreasing levels of pro-angiogenic mediators, VEGF, bFGF, IL-6, and IL-8, and inducing apoptosis through interference with the NF κ B signaling cascade. The specific aims as outlined in this proposal will help us to better understand the role of copper deficiency in tumor angiogenesis and apoptosis and may lead to a more specific approach to treat breast and other cancers.

Body:

Task 1: To determine the molecular mechanism whereby TM regulates NF κ B expression and activity in human breast cancers (Months 1-12).

We determined whether copper deficiency induced by TM is modulating NF κ B-mediated signaling. SUM149 and non-tumorigenic immortalized human mammary epithelial (HME) cells were transiently transfected with pNF κ B, a vector that contains four tandem copies of the κ B consensus sequence upstream of the luciferase reporter gene. Endogenous NF κ B activity was shown to be 2.5-fold higher in SUM149 cells in comparison to HME cells. This is consistent with our observation that p50 protein levels were significantly higher in SUM149 cells (data not shown). After treatment for 24 hours, TM inhibited luciferase activity by $62 \pm 2\%$ ($P < 0.001$, $n=6$) in SUM149 cells and $34 \pm 2\%$ ($P < 0.001$, $n=3$) in HME cells (Figure 1). Moreover, TM completely blocked TNF α -stimulated NF κ B activity in both cell lines. Similar results were observed at 48 and 72 hours demonstrating that TM is also able to inhibit NF κ B activity on a sustained basis without affecting cell survival under these conditions. As shown in Figure 2, we analyzed the binding of nuclear proteins from SUM149 cells to a labeled oligonucleotide spanning the κ B consensus sequence. Extracts from TM-treated cells showed a decrease in nuclear protein binding to the κ B consensus sequence. In addition, supershift analysis revealed that the predominant NF κ B components in SUM149 cells are p50, p52, and RelA. When cells were cultured with added copper (2 nM CuSO₄ addition), TM partially

lost its ability to regulate κ B binding and NF κ B transcriptional activity. Also, copper repletion partially reversed TM-inhibition of IL-6 and IL-8 mRNA expression, consistent with restoring NF κ B's ability to enhance transcription of these genes. Interestingly, p50 and RelA protein levels were reduced following treatment with TM in SUM149 cells suggesting that TM may be suppressing NF κ B activity by decreasing levels of NF κ B component proteins.







Figure 2. TM Decreases NFκB Binding and Protein Levels. **A**, Gel Shift Analysis. SUM149 cells were treated with vehicle or TM (1 nM) with or without the addition of 2nM CuSO₄ for 72 hours. Nuclear proteins were extracted, incubated with ³²P-labeled κB consensus sequence, and resolved by EMSA. **B**, Identification of NFκB Binding Complex. Supershift analysis was performed by pre-incubating nuclear extracts with p50, RelA, p52, c-Rel, or RelB antibody (Upstate Biotechnology) for 20 minutes on ice. **C**, p50 and RelA Protein Levels. SUM149 cells were treated with vehicle or TM (1 nM) for 72 hours. p50 and RelA levels were determined by Western blot analysis. Data is representative of three independent experiments.

Task 2: To determine if TM regulation of VEGF, bFGF, IL-6, and IL-8 is a direct consequence of inhibiting NFκB activity (Months 13-30).

We characterized the effect of NFκB suppression in SUM149 cells by genetically inhibiting NFκB with a dominant negative IκBα (S32AS36A). As shown in Figure 3, conditioned-media from SUM149 wildtype and SUM149-IκBαMut clones were collected and measured for VEGF, IL-1α, and IL-8 by ELISA. Secretion of these proangiogenic mediators by SUM149 wildtype cells was significantly inhibited following TM treatment (10 nM for 72 hours). Similarly, SUM149-IκBαMut clones 2 and 3 secreted lower amounts of these proangiogenic mediators in comparison to untransfected or empty-vector transfected SUM149 cells ($p < 0.05$) (Figure 2A). TM treatment of SUM149-IκBαMut clones resulted in no additional effect on inhibiting the amount of proangiogenic mediators. Since the change in phenotype observed for TM-treated SUM149 cells are similar to untreated SUM149-IκBαMut clones and TM did not change the phenotype of SUM149-IκBαMut clones, there is evidence that inhibition of tumor angiogenesis by TM is a direct consequence of TM's ability to suppress NFκB activation.



Key Research Accomplishments and Reportable Outcomes:

1. TM was found to significantly decrease NFκB protein levels and transcriptional activity.
2. TM was found to decrease the levels of potent proangiogenic mediators, VEGF, IL-1α, and IL-8.
3. We identified a major mechanism of the antiangiogenic effect of copper deficiency induced by TM is suppression of NFκB, contributing to a global inhibition of NFκB-mediated transcription of proangiogenic mediators.

Conclusions:

We have made significant progress in the past year in understanding how TM acts as an anti-angiogenic compound. TM was found to be an indirect anti-angiogenic by inhibiting NFκB activity of tumor cells resulting in decreased secretion of NFκB-dependent pro-angiogenic factor.

References:

1. Gilmore TD (1999) *Oncogene*, 18: 6842-6844.
2. Libermann TA and Baltimore D (1990) *Mol. Cell Biol.*, 10: 2327-2334.
3. Kunsch C and Rosen CA (1993) *Mol. Cell Biol.*, 13: 6137-6142.
4. van de Stolpe A, Caldenhoven E, Stade BG, Koenderman L, Raaijmakers JAM, Johnson JP, and van der Saag PT (1994) *J. Biol. Chem.*, 269: 6185-6192.
5. Iademarco MF, McQuillan JJ, Rosen GD, and Dean DC (1992) *J. Biol. Chem.*, 267: 16323-16329.
6. Novak U, Cocks BG, and Hamilton JA (1991) *Nucleic Acids Res.*, 19: 3389-3393.
7. Huang S, Robinson JB, DeGuzman A, Bucana CD, and Fidler IJ (2000) *Cancer Res.*, 60: 5334-5339.